Effects of Candesartan in Acute Stroke on Cognitive Function and Quality of Life: Results From the Scandinavian Candesartan Acute Stroke Trial [Brief Reports]
Conclusions—
Candesartan did not improve cognitive function or quality of life. Rather, there were signs of harmful effects. These findings support the conclusion from our previous report that there is no indication for routine blood pressure–lowering treatment with candesartan in the acute phase of stroke.
Clinical Trial Registration—
URL: www.clinicaltrials.gov. Unique identifier: NCT00120003.
Source: Stroke - Category: Neurology Authors: Hornslien, A. G., Sandset, E. C., Bath, P. M., Wyller, T. B., Berge, E., on Behalf of the Scandinavian Candesartan Acute Stroke Trial Study Group Tags: Cardiovascular Pharmacology, Cerebrovascular disease/stroke, Acute Stroke Syndromes, Other Stroke Treatment - Medical Brief Reports Source Type: research
More News: Cardiology | Cardiovascular | Clinical Trials | Drugs & Pharmacology | Heart | Hypertension | Men | Neurology | PET Scan | Statistics | Stroke | Study